Rheumatoid arthritis antibody succeeds in late-stage trial

The first Phase III trial of ocrelizumab has met its primary efficacy end point in patients with methotrexate-resistant rheumatoid arthritis.

by
In addition to rheumatoid arthritis, ocrelizumab is being studied in other autoimmune diseases including multiple sclerosis and lupus nephritis. (Photograph: DU CANE MEDICAL IMAGING LTD / SCIENCE PHOTO LIBRARY).
In addition to rheumatoid arthritis, ocrelizumab is being studied in other autoimmune diseases including multiple sclerosis and lupus nephritis. (Photograph: DU CANE MEDICAL IMAGING LTD / SCIENCE PHOTO LIBRARY).

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package